Search News ArchivesExhibitions & EventsWill BRIC be the Savior for the Life Sciences and Medical Devices Sector? BioCity to develop BioHub at Alderley Park Willetts’ announcement underpins need for accountability in research Seal of Approval for Pepceuticals New Pipet-X™ Pipette Controller – Reliable, Easy & Comfortable to Use IDT and SGI-DNA Broaden Their Collaboration to Provide Synthetic DNA Products up to 2 Mbp New Portable SPECTROSCOUT XRF Analyzer - the Lab that Goes Anywhere Novel RNA detection reagent enables gene expression analysis in living cells
Not happy with your ion chromatograph? Switch to Metrohm now and save! Debunking Myths about Peak Area Response of Glycoprotein Oligosaccharides Thermo Fisher Scientific Introduces Next Generation Ion Chromatography Suppressor ACE SuperC18 Ultra-Inert Extended pH Stability UHPLC and HPLC Columns Solid Phase Microextraction (SPME) Specialty Vials and Seals Merck Millipore to Highlight Capabilities in LC-MS at ASMS Revolutionize your pipetting with the new Biohit Picus electronic pipette Easy, Reliable Weighing in Regulated Areas Phenom proX all-in-one desktop SEM Flash of inspiration in the shaft tunnel - IKA launches the new video for UTTD control The only Chromatography Autosampler you will ever need! JG Finneran Associates introduces the 96-Well Multi-Tier Microtiter Plate System (Patented) IC for the people – Metrohm celebrates 25 years of ion chromatography
For further information or to sign up to receive any of our E-Newsletters click here Hitachi launches 3rd generation Tabletop Microscope BioTek releases Cytation™3 Cell Imaging Multi-Mode Reader Easy to use imaging and analysis with cellSens 1.8 Bruker and SCiLS GmbH Announce an Exclusive Partnership for SCiLS Lab Software for MALDI Imaging Definiens Extends Functionality of Leading Image and Data Analysis Solutions for Digital Pathology Qualoupe LIMS from Two Fold Software helps contract testing laboratories grow and develop business Ocean Optics Launches Powerful New Spectroscopy Software Thermo Fisher Scientific launches intuitive online tool for automation platform configuration Boehringer Ingelheim Implements Titian’s Mosaic Software to Manage New Biological Entity Samples Waters Biopharmaceutical, Bioanalysis and Screening Solutions Now Shipping with UNIFI 1.6 Molecular Devices Introduces SoftMax Pro 6 GxP Microplate Data Acquisition and Analysis Software |
Thermo Fisher Scientific Enables Ireland’s First Fragment-Based Screening Programme Thermo Fisher Scientific Inc.,
the world leader in serving science, today announced that the University of
Dublin has purchased the Maybridge Ro3 Diversity Fragment library for use in a
new drug discovery program. As an institution known for its world-class
biomedical research, the University is the first organization in the Republic
of Ireland to undertake a fragment-based screening programme. With possible
applications in the fight against viral replication, bacterial infections and
Alzheimer's disease, this research has the potential to provide significant
therapeutic advances. Dr. Neil Ferguson's team - the UCD Biomolecular Interactions Group - combines state-of-the-art biophysical and structural biology methodologies to unravel the molecular structures and forces that cause human diseases. By incorporating the Maybridge Ro3 library into his existing multi-disciplinary approach, Dr. Ferguson adds a new dimension to his team's research and their ability to identify potential drug compounds. The Ro3 library will enable the team to pursue challenging targets (such as those incompatible with conventional HTS programmes), neglected diseases and, in many cases, new targets emerging from his basic research programmes. "Combining the power of fragment-based drug discovery with our high-end instrumentation, we can effectively tackle our ever-expanding portfolio of therapeutic targets," said Dr. Ferguson. "Our aim is to identify novel leads that can develop into next-generation therapeutics. I gave long and serious consideration to the fragment library that we would use for this new initiative. Among the key criteria were the chemical diversity, validated solubility profiles and a proven track record in hit identification. The ready availability of its components in bulk format and their superior stability also makes the Maybridge Ro3 library an excellent choice for further development of the downstream medicinal chemistry." Dr. Ferguson concluded, "We feel that our current skill set, therapeutic targets, biophysical infrastructure and the Maybridge Ro3 library all place us well to make a serious fragment-based drug discovery effort within the academic sphere - watch this space!" The Maybridge Ro3 Diversity Fragment library is a resource of more than 1500, hand-selected, compound fragments and small molecule pharmacophores. Selection criteria include the compliance with the "Rule of Three" (Ro3) for lead generation and for the superior solubility profile of the compound. This highly diverse fragment library is available as three 500-compound sets; each compound in the library is pre-solubilised as a 1 mL, 10 mM solution, providing 10 µMol of 95 percent purity material dissolved in analytical grade DMSO. For further information on this product please visit www.maybridge.com. About Maybridge Products The Maybridge product line, part of Thermo Fisher Scientific, features highly innovative drug-like molecules and screening compounds for drug discovery and development. Available for both lab and development scale, the offering continually expands with the production of novel heterocyclic and phenyl ring-based chemical building blocks, including a unique and growing range of reactive intermediates. For more information about Maybridge brand products visit www.maybridge.com or call +44 18 40 77 05 67. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of nearly $11 billion, we have approximately 37,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through two premier brands, Thermo Scientific and Fisher Scientific, which offer a unique combination of continuous technology development and the most convenient purchasing options. Our products and services help accelerate the pace of scientific discovery, and solve analytical challenges ranging from complex research to routine testing to field applications. Visit www.thermofisher.com. |
June American Society for Mass Spectroscopy - Annual Conference (ASMS) 14th Annual Drug Discovery Leaders Summit 2013 Discovery Chemistry & Drug Design Congress 2013 5th Annual Drug Development Congress 2013 Single Cell Genomics & Transcriptomics Asia Congress 2013 Next Generation Sequencing Data Congress 2013 Malvern Instruments announces global agreement with Proveris Scientific Astronomy Researchers Relocate to Liverpool Science Park Fujifilm Diosynth Biotechnologies Commissions New Cell Banking Facility at Billingham, UK Site Malvern Instruments wins decisive victory over Wyatt Technology Corporation in US Court of Appeals |